Press release
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Eidos Therapeutics (Acoramidis (AG 10)), NeuraImmune Therapeutics (NI006)
"Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Transthyretin Amyloid Cardiomyopathy Therapeutics Market.
The report provides a detailed description of the Transthyretin Amyloid Cardiomyopathy drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Get a Detailed Overview of the Transthyretin Amyloid Cardiomyopathy Clinical Trial Activities and Regulatory Developments in the domain:
https://www.delveinsight.com/report-store/transthyretin-amyloid-cardiomyopathy-attr-cm-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Transthyretin Amyloid Cardiomyopathy therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Transthyretin Amyloid Cardiomyopathy treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Transthyretin Amyloid Cardiomyopathy drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Transthyretin Amyloid Cardiomyopathy treatment market.
Learn More about the Clinical and Commercial Development Activities in the Transthyretin Amyloid Cardiomyopathy Therapeutics Domain:
https://www.delveinsight.com/report-store/transthyretin-amyloid-cardiomyopathy-attr-cm-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
The Report Covers the Emerging Transthyretin Amyloid Cardiomyopathy Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Route of Administration
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Subcutaneous
• Intravenous
• Oral
• Intramuscular
Molecule Type
Products have been categorized under various Molecule types such as
• Small molecules
• Natural metabolites
• Monoclonal antibodies
Request for Sample PDF to Understand More About the Transthyretin Amyloid Cardiomyopathy Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/sample-request/transthyretin-amyloid-cardiomyopathy-attr-cm-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Transthyretin Amyloid Cardiomyopathy (ATTR-CM). Currently, NeuraImmune Therapeutics is leading the therapeutics market with its Transthyretin Amyloid Cardiomyopathy (ATTR-CM) drug candidates in the mid to advanced stage of clinical development.
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Companies in the Therapeutics Market Include:
• Eidos Therapeutics
• NeuraImmune Therapeutics
And Many Others
Emerging and Marketed Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Therapies Covered in the Report Include:
• Acoramidis (AG 10): Eidos Therapeutics
• NI006: NeuraImmune Therapeutics
And Many More
Get an in-depth Assessment of the Emerging Therapies and Transthyretin Amyloid Cardiomyopathy Companies Actively Working in the Market:
https://www.delveinsight.com/sample-request/transthyretin-amyloid-cardiomyopathy-attr-cm-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Transthyretin Amyloid Cardiomyopathy Current Treatment Patterns
4. Transthyretin Amyloid Cardiomyopathy - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Transthyretin Amyloid Cardiomyopathy Late-Stage Products (Phase-III)
7. Transthyretin Amyloid Cardiomyopathy Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Transthyretin Amyloid Cardiomyopathy Discontinued Products
13. Transthyretin Amyloid Cardiomyopathy Product Profiles
14. Transthyretin Amyloid Cardiomyopathy Companies
15. Transthyretin Amyloid Cardiomyopathy Drugs
16. Dormant and Discontinued Products
17. Transthyretin Amyloid Cardiomyopathy Unmet Needs
18. Transthyretin Amyloid Cardiomyopathy Future Perspectives
19. Transthyretin Amyloid Cardiomyopathy Analyst Review
20. Appendix
21. Report Methodology
Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/transthyretin-amyloid-cardiomyopathy-attr-cm-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
-------------------------------------------- xx --------------------------------------------
Other Trending Healthcare Reports by DelveInsight -
Radiofrequency Ablation Devices Market
https://www.delveinsight.com/report-store/radiofrequency-ablation-devices-market
Smart Inhalers Market
https://www.delveinsight.com/report-store/smart-inhalers-market
Persistent Depressive Disorder Market
https://www.delveinsight.com/report-store/persistent-depressive-disorder-market
Dysthymia Market
https://www.delveinsight.com/report-store/dysthymia-market
Nasopharyngeal Carcinoma Market
https://www.delveinsight.com/report-store/nasopharyngeal-carcinoma-market
Spinal Fusion Devices Market
https://www.delveinsight.com/report-store/spinal-fusion-devices-market
Stereotactic Surgery Devices Market
https://www.delveinsight.com/report-store/stereotactic-surgery-devices-market
Structural Heart Devices Global Market
https://www.delveinsight.com/report-store/structural-heart-devices-market-market
Intracardiac Echocardiography Devices Market
https://www.delveinsight.com/report-store/intracardiac-echocardiography-devices-market
Cardiac Monitoring System Market
https://www.delveinsight.com/report-store/cardiac-monitoring-system-market
Desmoplastic Small Round Cell Tumors (dsrcts) Market
https://www.delveinsight.com/report-store/desmoplastic-small-round-cell-tumors-market
Artificial Cornea and Corneal Implant Market
https://www.delveinsight.com/report-store/artificial-cornea-and-corneal-implant-market
Deep Brain Stimulation Devices Market
https://www.delveinsight.com/report-store/deep-brain-stimulation-devices-market
Obesity Market
https://www.delveinsight.com/report-store/weight-loss-weight-management-obesity-market
Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Eidos Therapeutics (Acoramidis (AG 10)), NeuraImmune Therapeutics (NI006) here
News-ID: 3134176 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Transthyretin
Evolving Market Trends In The Transthyretin Amyloidosis Treatment Industry: Inno …
The Transthyretin Amyloidosis Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Transthyretin Amyloidosis Treatment Market Size During the Forecast Period?
The market for transthyretin amyloidosis treatments has witnessed significant growth in the past few years. The market, which was valued at…
Transthyretin Amyloidosis Market Size, Share and Growth Report, 2034
On May 5 , 2025, Exactitude Consultancy., Ltd. released a research report titled "Transthyretin Amyloidosis Market". This report covers the global Transthyretin Amyloidosis market sales, sales volume, price, market share, ranking of major companies, etc., and provides a detailed analysis by region, country, product type, and application. It also forecasts the market size of automotive kick sensors based on market patterns from 2020 to 2034 and future market trends. Along…
What's Driving the Transthyretin Amyloidosis Treatment Market 2025-2034: Increas …
What Are the Projections for the Size and Growth Rate of the Transthyretin Amyloidosis Treatment Market?
The market for transthyretin amyloidosis treatment has seen robust growth in the past years. Its size is forecasted to increase from $5.52 billion in 2024 to $5.95 billion in 2025, with a compound annual growth rate (CAGR) of 7.8%. The surge in the market over the historic period is due to increased disease awareness, progress…
Unveiling Transthyretin Amyloidosis Treatment Market 2024
The transthyretin amyloidosis treatment market size has grown strongly in recent years. It will grow from $5.07 billion in 2023 to $5.52 billion in 2024 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to increased disease awareness, advancements in diagnostic tools, drug development and approvals, patient advocacy and support, collaboration in research..
The transthyretin amyloidosis treatment market size is…
Transthyretin Amyloidosis (ATTR) Market 2022 | Detailed Report
The top-notch information research report published by markets and markets is a vital asset that offers qualitative and quantitative factors of the Transthyretin Amyloidosis (ATTR) market. The research study and methodologies mentioned in the report examine the critical vendors by considering their contribution to the global market. Furthermore, the report offers an in-depth insight into leading players’ performance based on revenue generation and client requirements. Also, the research report reveals…
Anti-Transthyretin Global Market Research Report 2025
Anti-Transthyretin Report by Material, Application, and Geography � Global Forecast to 2022 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, united Kingdom, Japan, South Korea and China).
Access more details about this report at: https://www.research2reports.com/report-medical-devices/anti-transthyretin-market/80994
The report firstly introduced the Anti-Transthyretin basics: definitions, classifications, applications and market overview;…
